Previous close | 80.89 |
Open | 81.44 |
Bid | 80.30 x 900 |
Ask | 80.32 x 1300 |
Day's range | 80.14 - 81.71 |
52-week range | 68.84 - 91.00 |
Volume | |
Avg. volume | 6,299,409 |
Market cap | 106.558B |
Beta (5Y monthly) | 0.78 |
PE ratio (TTM) | 25.48 |
EPS (TTM) | 3.15 |
Earnings date | 23 May 2024 |
Forward dividend & yield | 2.76 (3.41%) |
Ex-dividend date | 21 Mar 2024 |
1y target est | 94.00 |
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
Medtronic (MDT) closed at $80.86 in the latest trading session, marking a +1.4% move from the prior day.
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time, keeping therapy in harmony with the motions of daily life.